立体定向体部放疗治疗乳腺癌寡转移:系统综述与荟萃分析
该系统综述与荟萃分析纳入10项研究共467例乳腺癌寡转移患者和653个转移灶,评估立体定向消融放疗(SABR)的疗效与安全性。结果显示1年和2年局部控制率分别为97%和90%,总生存率分别为93%和81%,2-3级毒性发生率低。SABR安全且局部控制率高。
要点
- SABR治疗乳腺癌寡转移的1年和2年局部控制率分别为97%和90%。
- 1年和2年总生存率分别为93%和81%,2-3级毒性发生率低。
- 前瞻性设计和仅骨转移与更好的总生存显著相关。
核心结论
- SABR治疗乳腺癌寡转移安全且局部控制率高。
- 需要更长期随访和正在进行的前瞻性试验进一步明确该策略的作用。
研究设计与样本
- 遵循PRISMA和MOOSE指南的系统综述与荟萃分析。
- 检索Medline、Embase、Cochrane Library及1990年至2021年6月的年会论文集。
- 纳入10项研究,共467例患者和653个治疗转移灶。
- 进行荟萃回归分析评估调节变量与结局的相关性,p<0.05为显著。
主要发现
- 1年局部控制率为97%(95% CI 95-99%),2年局部控制率为90%(95% CI 84-94%)。
- 1年总生存率为93%(95% CI 89-96%),2年总生存率为81%(95% CI 72-88%)。
- 任何2级毒性发生率为4.1%(95% CI 0.1-5%),3级毒性发生率为0.7%(95% CI 0-1%)。
- 荟萃回归分析中,仅前瞻性设计(p=0.001)和仅骨转移(p=0.01)与更好的总生存显著相关。
- 亚组分析中,HER2+、HR+/HER2(-)和三阴性乳腺癌的2年总生存率分别为100%、86%和32%,p=0.001。
临床怎么用
- SABR可作为乳腺癌寡转移患者的一种安全治疗选择,局部控制率高。
- 对于三阴性乳腺癌寡转移患者,SABR后的总生存可能较差,需个体化评估。
局限性
- 现有数据随访时间较短,需要更长期随访。
- 纳入研究数量有限(10项),且仅前瞻性设计与更好总生存相关,提示回顾性研究可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Stereotactic ablative radiotherapy (SABR) has been reported to be an effective treatment for oligometastatic disease from different primary cancer sites. Here we assess the effectiveness and safety of SABR for oligometastatic breast cancer patients by performing a meta-analysis. METHODS: Following PRISMA and MOOSE guidelines, a systematic review and meta-analysis was performed. Eligible studies were identified on Medline, Embase, Cochrane Library, and annual meetings proceedings from 1990 to June 2021. A meta-regression analysis was performed to assess if there was a correlation between moderator variables and outcomes, and a p-value <0.05 was considered significant. RESULTS: Ten studies met criteria for inclusion, comprising 467 patients and 653 treated metastases. The 1- and 2-year local control rates were 97% (95% CI 95-99%), and 90% (95% CI 84-94%), respectively. Overall survival (OS) was 93% (95% CI 89-96%) at 1 year, 81% (95% CI 72-88%) at 2 years. The rate of any grade 2 or 3 toxicity was 4.1 % (95% CI 0.1-5%), and 0.7% (0-1%), respectively. In the meta-regression analysis, only prospective design (p = 0.001) and bone-only metastases (p = 0.01) were significantly associated with better OS. In the subgroup analysis, the OS at 2y were significantly different comparing HER2+, HR+/HER2(-) and triple negative breast cancer 100%, 86% and 32%, p = 0.001. For local control outcomes, hormone receptor status (p = 0.01) was significantly associated on meta-regression analysis. CONCLUSION: SABR for oligometastatic breast cancer is safe and associated with high rates of local control. Longer follow-up of existing data and ongoing prospective trials will help further define the role of this management strategy.
引用
- Viani GA, Gouveia AG, Louie AV, et al. Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis. Radiother Oncol. 2021. PMID: 34624408. doi:10.1016/j.radonc.2021.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。